Sigma Foods (SIGMAF) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 Feb, 2026Executive summary
Record 2025 revenues surpassed $9.3 billion, with EBITDA reaching $1 billion and double-digit ROIC maintained in a dynamic macro environment.
Strong performance was driven by diversified operations, selective price actions, and favorable FX, with Mexico and Europe leading growth.
Completed the spin-off of Alpek, now reported as discontinued operations, and rebranded as Sigma Foods with a new ticker symbol.
Strategic focus remains on operational excellence, brand innovation, capacity expansion, and future-oriented innovation.
Financial highlights
4Q25 revenues reached $2.5 billion, up 12–13% year-over-year, with full-year revenues up 4% to $9.273 billion.
4Q25 EBITDA was $278 million, with comparable EBITDA at $284 million, up 28–34% year-over-year; full-year comparable EBITDA reached $1 billion.
Net income in 4Q25 was $177 million, compared to a $320 million loss in 4Q24; full-year net income was $462 million, up from $52 million in 2024.
Net debt at year-end was $2.705 billion, with Net Debt/EBITDA at 2.5x and total liquidity at $1.5 billion.
CapEx totaled $362 million for 2025, up 45–47% year-over-year, reflecting capacity expansions and modernization.
Outlook and guidance
2026 guidance projects 4% revenue growth, 5–10% EBITDA growth, and 2% volume growth, with all regions contributing.
CapEx for 2026 is expected to increase 27% to $460 million, mainly for capacity replacement in Spain and expansions in Mexico and the U.S.
Proposed 2026 cash dividend of $150 million, to be paid in installments.
Latest events from Sigma Foods
- Record 4Q25 EBITDA, strong innovation, and sustainability progress drive growth outlook.SIGMAF
Corporate presentation25 Feb 2026 - EBITDA and guidance rose on Sigma's record results, with debt reduction and transformation progressing.SIGMAF
Q2 20242 Feb 2026 - Sigma posts record EBITDA as ALFA advances Alpek spin-off and targets lower leverage.SIGMAF
Q3 202418 Jan 2026 - Record results and transformation position for growth as Alpek spin-off nears completion.SIGMAF
Q4 202419 Dec 2025 - Record revenues and sequential EBITDA gains despite cost and operational headwinds.SIGMAF
Q3 202514 Dec 2025 - Transformation complete, 1Q25 EBITDA at US$220M, S&P upgrades to 'BBB'.SIGMAF
Q1 202529 Nov 2025 - Record 2Q25 revenues and EBITDA, with insurance gains and strategic transformation completed.SIGMAF
Q2 202513 Nov 2025